| 000 | 01718 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250514011959.0 | ||
| 264 | 0 | _c20011204 | |
| 008 | 200112s 0 0 eng d | ||
| 022 | _a0014-2980 | ||
| 024 | 7 |
_a10.1002/1521-4141(2001010)31:10<3016::aid-immu3016>3.0.co;2-j _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCarson, W E | |
| 245 | 0 | 0 |
_aInterleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. _h[electronic resource] |
| 260 |
_bEuropean journal of immunology _cOct 2001 |
||
| 300 |
_a3016-25 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xtherapeutic use |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 | _aAntibody-Dependent Cell Cytotoxicity |
| 650 | 0 | 4 |
_aBreast Neoplasms _ximmunology |
| 650 | 0 | 4 |
_aCD56 Antigen _xanalysis |
| 650 | 0 | 4 |
_aCytokines _xbiosynthesis |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInterleukin-2 _xpharmacology |
| 650 | 0 | 4 |
_aKiller Cells, Natural _xdrug effects |
| 650 | 0 | 4 | _aLymphocyte Activation |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 |
_aReceptor, ErbB-2 _xanalysis |
| 650 | 0 | 4 |
_aReceptors, IgG _xphysiology |
| 650 | 0 | 4 | _aTrastuzumab |
| 650 | 0 | 4 | _aTumor Cells, Cultured |
| 700 | 1 | _aParihar, R | |
| 700 | 1 | _aLindemann, M J | |
| 700 | 1 | _aPersoneni, N | |
| 700 | 1 | _aDierksheide, J | |
| 700 | 1 | _aMeropol, N J | |
| 700 | 1 | _aBaselga, J | |
| 700 | 1 | _aCaligiuri, M A | |
| 773 | 0 |
_tEuropean journal of immunology _gvol. 31 _gno. 10 _gp. 3016-25 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/1521-4141(2001010)31:10<3016::aid-immu3016>3.0.co;2-j _zAvailable from publisher's website |
| 999 |
_c11512224 _d11512224 |
||